These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 37569547)

  • 1. Knockdown of PTK7 Reduces the Oncogenic Potential of Breast Cancer Cells by Impeding Receptor Tyrosine Kinase Signaling.
    Shin WS; Oh SW; Park HN; Kim JH; Lee ST
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein Tyrosine Kinase 7 Regulates EGFR/Akt Signaling Pathway and Correlates With Malignant Progression in Triple-Negative Breast Cancer.
    Cui NP; Qiao S; Jiang S; Hu JL; Wang TT; Liu WW; Qin Y; Wang YN; Zheng LS; Zhang JC; Ma YP; Chen BP; Shi JH
    Front Oncol; 2021; 11():699889. PubMed ID: 34367983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catalytically inactive receptor tyrosine kinase PTK7 activates FGFR1 independent of FGF.
    Shin WS; Lee HW; Lee ST
    FASEB J; 2019 Nov; 33(11):12960-12971. PubMed ID: 31490704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTK 7 is a transforming gene and prognostic marker for breast cancer and nodal metastasis involvement.
    Gärtner S; Gunesch A; Knyazeva T; Wolf P; Högel B; Eiermann W; Ullrich A; Knyazev P; Ataseven B
    PLoS One; 2014; 9(1):e84472. PubMed ID: 24409301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTK7, a Catalytically Inactive Receptor Tyrosine Kinase, Increases Oncogenic Phenotypes in Xenograft Tumors of Esophageal Squamous Cell Carcinoma KYSE-30 Cells.
    Shin WS; Park MK; Kim JH; Oh SW; Jang JY; Lee H; Lee ST
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic role of protein tyrosine kinase 7 in esophageal squamous cell carcinoma.
    Shin WS; Kwon J; Lee HW; Kang MC; Na HW; Lee ST; Park JH
    Cancer Sci; 2013 Aug; 104(8):1120-6. PubMed ID: 23663482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
    Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
    BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catalytically defective receptor protein tyrosine kinase PTK7 enhances invasive phenotype by inducing MMP-9 through activation of AP-1 and NF-κB in esophageal squamous cell carcinoma cells.
    Shin WS; Hong Y; Lee HW; Lee ST
    Oncotarget; 2016 Nov; 7(45):73242-73256. PubMed ID: 27689325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
    Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
    Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Desmoglein 2 and desmocollin 2 depletions promote malignancy through distinct mechanisms in triple-negative and luminal breast cancer.
    Han JY; Che N; Mo J; Zhang DF; Liang XH; Dong XY; Zhao XL; Sun BC
    BMC Cancer; 2024 Apr; 24(1):532. PubMed ID: 38671389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway.
    Han J; Yu J; Dai Y; Li J; Guo M; Song J; Zhou X
    Bosn J Basic Med Sci; 2019 Feb; 19(1):52-59. PubMed ID: 29924958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR3 signaling and function in triple negative breast cancer.
    Chew NJ; Nguyen EV; Su SP; Novy K; Chan HC; Nguyen LK; Luu J; Simpson KJ; Lee RS; Daly RJ
    Cell Commun Signal; 2020 Jan; 18(1):13. PubMed ID: 31987043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a Resistance Mechanism to IGF-IR Targeting in Human Triple Negative MDA-MB-231 Breast Cancer Cells.
    Tsui J; Qi S; Perrino S; Leibovitch M; Brodt P
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33916323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tryptophan hydroxylase 1 and 5-HT
    Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
    Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells.
    Rigiracciolo DC; Santolla MF; Lappano R; Vivacqua A; Cirillo F; Galli GR; Talia M; Muglia L; Pellegrino M; Nohata N; Di Martino MT; Maggiolini M
    J Exp Clin Cancer Res; 2019 Feb; 38(1):58. PubMed ID: 30728047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation.
    Yao W; Feng D; Bian W; Yang L; Li Y; Yang Z; Xiong Y; Zheng J; Zhai R; He J
    Amino Acids; 2012 Nov; 43(5):2027-35. PubMed ID: 22476347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of TRIM66 in MDA-MB-468 triple negative breast cancer cell line suppresses proliferation and promotes apoptosis through EGFR signaling.
    Zhang H; Zheng Y; Zhang Y
    Pol J Pathol; 2021; 72(2):160-166. PubMed ID: 34706523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
    Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
    Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
    Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA
    Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.